Analysis
KymaThera has raised an $80 million Series B led by Alta Partners, with Venrock, Foresite Capital and J. Wood Capital also participating, according to Pulse2.com. The round brings the biotech's total funding to more than $100 million and will fund KymaThera's push toward Phase 1 dosing of its lead drug, K-1728, expected to begin in the fourth quarter of 2026.
Why selectivity is the whole pitch
K-1728 is an oral PI3K-alpha inhibitor, a drug class already clinically validated -- Novartis's alpelisib (Piqray) won FDA approval for PI3K-alpha-mutated breast cancer in 2019 -- but one that has struggled with toxicity because inhibiting PI3K-alpha also disrupts normal insulin signaling, causing hyperglycemia, along with rash and other side effects that force dose reductions in a meaningful share of patients. KymaThera says K-1728 selectively inhibits both kinase-domain and helical-domain PI3K-alpha mutations while sparing wild-type PI3K-alpha, the mechanism it says drives that toxicity. The molecule was discovered internally on the company's own platform and remains wholly owned, with no licensing partner to share future royalties or milestone payments.
“Dose-escalation data due after the Q4 2026 start will be the first real test of whether the mechanism holds up outside the lab.”
KymaThera is initially targeting HR-positive/HER2-negative breast cancer, both as a monotherapy and in combination regimens, plus PI3K-alpha-driven vascular malformations as a separate monotherapy indication -- a narrower, biomarker-defined population than alpelisib's broader approval, typical of next-generation inhibitors trying to differentiate on tolerability rather than efficacy alone.
The competitive landscape for next-gen PI3K inhibitors includes Relay Therapeutics and Olema Oncology, both also chasing better-tolerated alternatives to first-generation PI3K-alpha drugs, alongside larger pharma programs inside Novartis and Roche defending their existing franchises. A clean selectivity profile would let KymaThera compete on a drug's ability to stay at therapeutic dose without the glucose-management burden that limits alpelisib compliance today.
The limitation is one every preclinical biotech story shares: KymaThera's selectivity claims are based on its own internal data and have not yet been tested in Phase 1 patients, where real-world tolerability -- not a binding assay -- is the only evidence that counts. Dose-escalation data due after the Q4 2026 start will be the first real test of whether the mechanism holds up outside the lab.
For biotech-focused LPs, $80 million is a meaningful Series B for a company with no clinical data yet -- a bet on mechanism and management, with three specialist healthcare investors plus new entrant J. Wood Capital, rather than on de-risked trial results.